<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164878">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01996397</url>
  </required_header>
  <id_info>
    <org_study_id>2013/140</org_study_id>
    <nct_id>NCT01996397</nct_id>
  </id_info>
  <brief_title>Acute Feedback on Left ventrIcular Lead Implantation Location for Cardiac Resynchronization Therapy</brief_title>
  <acronym>CCI impact</acronym>
  <official_title>Acute Feedback on Left ventrIcular Lead Implantation Location for Cardiac Resynchronization Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Center for Cardiological Innovation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic Bakken Research Center</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <authority>Norway: Regional Ethics Commitee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exploratory, prospective, interventional, non-randomized single-center research study to
      compare metrics derived from 2 or 3-D reconstructions of lead movement, bioimpedance and VCG
      to augmentation of left ventricular contractility (LV dP/dt max) at different pacing
      configurations in patients undergoing a CRT-implant. Pacing sites and contractility data
      will be compared to pre operative cardiac ultrasound and MRI metrics.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>dP\dt max response to different ventricular lead pacing sites</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To compare metrics derived from 2 or 3-D reconstructions of lead movement to augmentation of left ventricular contractility (LV dP/dt max) at different pacing configurations in patients undergoing a CRT-implant Main objective is to identify the optimal LV pacing site within each patient where the force of contraction during BiV pacing is maximized and to assess the feasibility of a non-invasive sensor to identify this optimal site.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lead movements and electrical measures</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare metrics derived from 2/3-D reconstructions of lead movement to electrical measures (e.g. Q-LV-timing or VCG) at different pacing configurations in patients undergoing a CRT-implant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metrics derived from 2/3-D reconstructions of lead movement and  Force-Interval-Relation</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare metrics derived from 2/3-D reconstructions of lead movement to Force-Interval-Relation at different pacing configurations in patients undergoing a CRT-implant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metrics derived from 2/3-D reconstructions of lead movement and CardioGuide Motion Map</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare metrics derived from 2/3-D reconstructions of lead movement to CardioGuide Motion Map at different pacing configurations in patients undergoing a CRT-implant.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Heart Failure</condition>
  <condition>Resynchronization Therapy</condition>
  <condition>Assessment of Acute CRT Response</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiac resynchronization therapy device implantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is indicated for CRT or CRT-D device according to current applicable ESC/AHA
             guidelines

          -  Subject is in stable sinus rhythm at the time of implant (no atrial arrhythmias
             lasting &gt; 30 seconds during the last 2 weeks prior to inclusion). No documented
             AF-episodes allowed during the last 2 weeks prior to inclusion.

          -  Subject receives optimal heart failure oral medical therapy (ACE inhibitor and/or ARB
             and Beta Blockers), and is on a stable medication scheme for at least 2 months prior
             to enrollment.

          -  Subject (or the legal guardian) is willing to sign informed consent form

        Exclusion Criteria:

          -  Permanent atrial fibrillation/ flutter or tachycardia

          -  RBBB

          -  Recent myocardial infarction (MI), within 40 days prior to enrollment. Subject
             underwent coronary artery bypass graft (CABG) or valve surgery, within 90 days prior
             to enrollment

          -  Post heart transplantation, or is actively listed on the transplantation list, or has
             reasonable probability (per investigator's discretion) of undergoing transplantation
             in the next year

          -  Implanted with a left ventricular assist device (LVAD), or has reasonable probability
             (per investigator's discretion) of receiving a LVAD in the next year

          -  On chronic renal dialysis, or with severe renal disease (defined as estimated
             Glomerular Filtration Rate (equation provided by Modification of Diet in Renal
             Disease study): (eGFR) &lt; 30 mL/min/1.73m2)

          -  On continuous or uninterrupted infusion (inotropic) therapy for heart failure (â‰¥ 2
             stable infusions a week)

          -  Severe aortic stenosis (with a valve area of &lt;1.0 cm2 or significant valve disease
             expected to be operated on within study period)

          -  Complex and uncorrected congenital heart disease

          -  Mechanical heart valve

          -  Breastfeeding women, or women of child bearing potential and who are not on a
             reliable form of birth control

          -  Enrolled in one or more concurrent studies that would confound the results of this
             study

          -  Already implanted with pacemaker (CRT, CRT-D, ICD) and needs replacement
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Erik Kongsgaard, M.D, Ph.d</last_name>
    <phone>004790216297</phone>
    <email>erik.kongsgard@medisin.uio.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hans Henrik Odland, M.D</last_name>
    <phone>004790509944</phone>
    <email>h.h.odland@medisin.uio.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oslo University Hospital, Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Erik Kongsgaard, M.D, Ph.d</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <link>
    <url>http://www.heart-sfi.no/</url>
    <description>Center for Cardiological Innovation</description>
  </link>
  <link>
    <url>http://www.oslo-universitetssykehus.no</url>
    <description>Oslo University Hospital</description>
  </link>
  <reference>
    <citation>Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004 May 20;350(21):2140-50.</citation>
    <PMID>15152059</PMID>
  </reference>
  <reference>
    <citation>Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005 Apr 14;352(15):1539-49. Epub 2005 Mar 7.</citation>
    <PMID>15753115</PMID>
  </reference>
  <reference>
    <citation>Butter C, Auricchio A, Stellbrink C, Fleck E, Ding J, Yu Y, Huvelle E, Spinelli J; Pacing Therapy for Chronic Heart Failure II Study Group. Effect of resynchronization therapy stimulation site on the systolic function of heart failure patients. Circulation. 2001 Dec 18;104(25):3026-9.</citation>
    <PMID>11748094</PMID>
  </reference>
  <reference>
    <citation>Rossillo A, Verma A, Saad EB, Corrado A, Gasparini G, Marrouche NF, Golshayan AR, McCurdy R, Bhargava M, Khaykin Y, Burkhardt JD, Martin DO, Wilkoff BL, Saliba WI, Schweikert RA, Raviele A, Natale A. Impact of coronary sinus lead position on biventricular pacing: mortality and echocardiographic evaluation during long-term follow-up. J Cardiovasc Electrophysiol. 2004 Oct;15(10):1120-5.</citation>
    <PMID>15485432</PMID>
  </reference>
  <reference>
    <citation>Mullens W, Verga T, Grimm RA, Starling RC, Wilkoff BL, Tang WH. Persistent hemodynamic benefits of cardiac resynchronization therapy with disease progression in advanced heart failure. J Am Coll Cardiol. 2009 Feb 17;53(7):600-7. doi: 10.1016/j.jacc.2008.08.079.</citation>
    <PMID>19215835</PMID>
  </reference>
  <reference>
    <citation>Butter C, Stellbrink C, Belalcazar A, Villalta D, Schlegl M, Sinha A, Cuesta F, Reister C. Cardiac resynchronization therapy optimization by finger plethysmography. Heart Rhythm. 2004 Nov;1(5):568-75.</citation>
    <PMID>15851221</PMID>
  </reference>
  <reference>
    <citation>Whinnett ZI, Davies JE, Willson K, Chow AW, Foale RA, Davies DW, Hughes AD, Francis DP, Mayet J. Determination of optimal atrioventricular delay for cardiac resynchronization therapy using acute non-invasive blood pressure. Europace. 2006 May;8(5):358-66.</citation>
    <PMID>16635996</PMID>
  </reference>
  <reference>
    <citation>Whinnett ZI, Davies JE, Willson K, Manisty CH, Chow AW, Foale RA, Davies DW, Hughes AD, Mayet J, Francis DP. Haemodynamic effects of changes in atrioventricular and interventricular delay in cardiac resynchronisation therapy show a consistent pattern: analysis of shape, magnitude and relative importance of atrioventricular and interventricular delay. Heart. 2006 Nov;92(11):1628-34. Epub 2006 May 18.</citation>
    <PMID>16709698</PMID>
  </reference>
  <reference>
    <citation>Jia P, Ramanathan C, Ghanem RN, Ryu K, Varma N, Rudy Y. Electrocardiographic imaging of cardiac resynchronization therapy in heart failure: observation of variable electrophysiologic responses. Heart Rhythm. 2006 Mar;3(3):296-310.</citation>
    <PMID>16500302</PMID>
  </reference>
  <reference>
    <citation>Tysler M, Kneppo P, TurzovÃ¡ M, SvehlÃ­kovÃ¡ J, Karas S, HeblÃ¡kovÃ¡ E, HÃ¡na K, FilipovÃ¡ S. Noninvasive assessment of local myocardium repolarization changes using high resolution surface ECG mapping. Physiol Res. 2007;56 Suppl 1:S133-41. Epub 2007 May 31.</citation>
    <PMID>17552884</PMID>
  </reference>
  <reference>
    <citation>van Deursen C, van Geldorp IE, Rademakers LM, van Hunnik A, Kuiper M, Klersy C, Auricchio A, Prinzen FW. Left ventricular endocardial pacing improves resynchronization therapy in canine left bundle-branch hearts. Circ Arrhythm Electrophysiol. 2009 Oct;2(5):580-7. doi: 10.1161/CIRCEP.108.846022. Epub 2009 Aug 10.</citation>
    <PMID>19843927</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 21, 2013</lastchanged_date>
  <firstreceived_date>November 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Erik Kongsgaard</investigator_full_name>
    <investigator_title>MD, Ph.d</investigator_title>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Bundle branch block</keyword>
  <keyword>CRT response</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
